Welcome to Iris Biotech
For better service please confirm your country and language we detected.
For better service please confirm your country and language we detected.
Thank you very much for your interest in our products. All prices listed on our website are ex-works, Germany, and may attract customs duties when imported.
You may/will be contacted by the shipping company for additional documentation that may be required by the US Customs for clearance.
We offer you the convenience of buying through a local partner, Peptide Solutions LLC who can import the shipment as well as prepay the customs duties and brokerage on your behalf and provide the convenience of a domestic sale.
Continue to Iris Biotech GmbHSend request to US distributorChemischer Name: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(gamma-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH // Synonyme: N26-(Hexadecanoyl-gamma-glutamyl)-(34-arginine)GLP-1-(7-37), (Lys(gamma-Glu-palmitoyl)26,Arg34)-GLP-1 (7-37), One letter Code: HAEGTFTSDVSSYLEGQAAK(gamma-Glu-palmitoyl)EFIAWLVRGRG
Ab auf Anfrage
Glucagon-Like-Peptide-1 (GLP-1) agonist used for the treatment of type 2 diabetes. It is an incretin mimetic stimulating the release and synthesis of insulin into the blood by the intestine in response to food. It is only active in the presence of high circulating glucose levels. It also slows the passage of food through the gut and reduces appetite.
Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide; I. Guryanov, A. Bondesan, D. Visentini, A. Orlandin, B. Biondi, C. Toniolo, F. Formaggio, A. Ricci, J. Zanon and W. Cabri; J Pept Sci 2016; 22: 471-9. https://doi.org/10.1002/psc.2890
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide; J. Lau, P. Bloch, L. Schäffer, I. Pettersson, J. Spetzler, J. Kofoed, K. Madsen, L. B. Knudsen, J. McGuire, D. B. Steensgaard, H. M. Strauss, D. X. Gram, S. M. Knudsen, F. S. Nielsen, P. Thygesen, S. Reedtz-Runge and T. Kruse; Journal of medicinal chemistry 2015; 58: 7370-7380. https://doi.org/10.1021/acs.jmedchem.5b00726
The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates; C. F. Gotfredsen, A. M. Molck, I. Thorup, N. C. Nyborg, Z. Salanti, L. B. Knudsen and M. O. Larsen; Diabetes 2014; 63: 2486-97. https://doi.org/10.2337/db13-1087
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors; J. J. Neumiller; J Am Pharm Assoc (2003) 2009; 49 Suppl 1: S16-29. https://doi.org/10.1331/JAPhA.2009.09078
Liraglutide in type 2 diabetes: from pharmacological development to clinical practice; M. C. Rossi and A. Nicolucci; Acta Biomed 2009; 80: 93-101.
Potential of liraglutide in the treatment of patients with type 2 diabetes; C. F. Deacon; Vasc Health Risk Manag 2009; 5: 199-211. https://doi.org/10.2147/vhrm.s4039